HCA Warning, Leqembi SubQ, FTC Insulin, ICER Expansion

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, I've had today's topics circled since this morning, particularly the HCA situation and the Leqembi approval.

MarcusSame here. We're looking at HCA's profit warning — what it means for hospital finances and downstream access. Then subQ Leqembi's approval and the new HEOR questions it raises. Third, the FTC insulin settlement with CVS Caremark. And finally, ICER's expanded scientific advice program.

SaraThat second one is interesting to me — the administration cost questions for subQ Leqembi could significantly alter budget impact calculations beyond just drug acquisition.

MarcusExactly. Let's get into it.

MarcusHCA Healthcare's profit warning is the first story. They cited increased uncompensated care and Medicaid shortfalls, signaling broader financial stress in US hospitals. This isn't just about HCA; it's a bellwether for hospital systems nationwide, potentially squeezing budgets for new therapies.

SaraAbsolutely. And what strikes me is how this creates a vicious cycle: hospitals under financial pressure may delay high-cost innovations, which then reduces evidence generation opportunities. It's a system-level access challenge.

MarcusThat connects to something I keep coming back to — the hidden cost of uncompensated care. When hospitals absorb losses, it's not just their balance sheet; it's the entire ecosystem that feels the pinch, from R&D budgets to patient access programs.

SaraRight, and from the payer side, this makes the budget impact conversation even more urgent. If hospitals are cutting costs, payers will face tougher negotiations on product pricing. The opportunity cost question just got sharper.

MarcusI wonder if that's the full picture though. Couldn't this also accelerate value-based contracting? If hospitals are desperate for solutions, they might be more open to innovative payment models tied to outcomes.

SaraThat's one read — I'd frame it slightly differently. My sense is that financial distress makes systems risk-averse, not innovative. They'll prioritize proven therapies over novel ones with uncertain reimbursement pathways. The evidence bar gets higher, not lower.

MarcusFair point. The part that gives me pause is how this affects R&D investment decisions. If hospital systems pull back, it reduces real-world data generation, which is critical for HEOR. It's a downstream effect many aren't considering.

SaraExactly. And that's why this story matters right now — it's not just a hospital finance issue; it's a market access infrastructure problem.

MarcusNext, the FDA approval of subcutaneous Leqembi for Alzheimer's. This formulation expands patient access by reducing infusion burden, but it introduces new HEOR questions around administration costs and adherence.

SaraWhat strikes me here is the budget impact calculus. SubQ administration requires nursing time and training, which adds significant hidden costs beyond the drug price. Payers will need new models to capture these.

MarcusThat's fair, though I think payers would see it differently initially. The immediate focus will be on acquisition cost differential versus IV. But you're right — the real value conversation has to include total cost of care.

SaraAnd I'd push back slightly on that. The first wave of HTA submissions will likely ignore administration costs because they're not in the label. It'll take real-world evidence to shift that narrative, which takes time.

MarcusWhat strikes me about that is the evidence generation timeline. We need RWE on adherence and resource utilization now, but manufacturers will prioritize label expansion first. There's a mismatch there.

SaraExactly. And this is one of those stories where the innovation outpaces the evidence framework. The field hasn't worked out how to value convenience in cost-effectiveness models yet.

MarcusThe part that gives me pause is how this affects comparative effectiveness. If subQ improves adherence but increases nursing burden, does it truly improve outcomes? That's the HEOR question that will determine access.

SaraRight, and from the payer side, that's where the budget impact becomes critical. If adherence gains are modest but resource use spikes, the net value could be negative. We need those real-world numbers.

MarcusI keep coming back to the patient perspective here. Burden reduction matters, but only if it translates to meaningful health gains. The evidence has to prove that.

MarcusThe FTC settlement with CVS Caremark over insulin pricing is the third story. They're refunding $78.4 million to consumers, reinforcing scrutiny on PBM practices and pricing transparency.

SaraWhat's striking here is the signal this sends to PBMs. When the FTC steps in, it's not just about refunds; it's about fundamentally changing how rebates and fees are structured. That could ripple through the entire supply chain.

MarcusThat's one read — I'd frame it slightly differently. This settlement shows that regulatory pressure is shifting from drug manufacturers to intermediaries. It's a recognition that PBMs hold disproportionate pricing power.

SaraAnd I'd push back slightly on that. The $78.4 million figure is tiny in the context of the insulin market. This feels more like a symbolic move than a structural change. The real question is whether it leads to broader PBM reform.

MarcusThe part that gives me pause is how this affects manufacturer negotiations. If PBMs face more transparency demands, manufacturers might have to rethink rebate strategies. It could actually increase net prices in the short term.

SaraRight, and from the payer side, that's where the opportunity cost question gets complicated. If insulin prices don't come down, budgets for innovative therapies get squeezed. This settlement doesn't solve the underlying access problem.

MarcusI wonder if that's the full picture though. Couldn't this accelerate value-based contracts for insulin? If PBMs are under pressure, they might be more open to outcomes-based models that actually reduce waste.

SaraThat's fair, but I'm skeptical. The system is so entrenched in fee-for-service that shifting to value-based models requires more than one settlement. This is a step, not a solution.

MarcusThe thread running through this is how it affects evidence generation. If PBMs are less willing to share data, RWE becomes harder to generate. That's the hidden consequence.

MarcusFinally, ICER's expanded scientific advice program. They're engaging earlier with manufacturers and payers, which could reshape evidence generation timelines and HTA alignment.

SaraWhat strikes me here is the resource question. Earlier advice means more manufacturer submissions and more payer reviews. That increases the burden on both sides without clear evidence of improved outcomes.

MarcusThat's one read — I'd frame it slightly differently. Early alignment could prevent late-stage rejections, saving everyone time and money. It's about reducing uncertainty in the process.

SaraAnd I'd push back slightly on that. The evidence doesn't show that early advice consistently leads to better HTA outcomes. In fact, it can create false expectations if the advice isn't binding. That's a methodological concern.

MarcusThe part that gives me pause is how this affects innovation. If manufacturers have to engage earlier, it might delay launches for therapies that don't fit traditional HTA frameworks. That could stifle novel approaches.

SaraRight, and from the payer side, there's the opportunity cost. If ICER spends more time on early advice, they have less capacity for core assessments. That's a trade-off the field hasn't fully worked out.

MarcusI keep coming back to the patient perspective here. If this leads to faster, more aligned decisions, that's good for access. But if it creates more complexity, it could backfire.

SaraExactly. And this is one of those stories where the intention is positive but the execution matters. The real question is whether payers will actually use the advice or just treat it as preliminary.

MarcusThe unifying observation is how all these stories reflect system tensions: financial pressures, innovation vs. cost, regulatory shifts, and evidence evolution. It's a lot to sit with.

SaraA lot to think about today. I'll be watching how HCA's financial stress impacts hospital formulary decisions for high-cost therapies. That could be the next access domino to fall.

MarcusSame — and for me the thread running through today is how intermediaries are becoming the new battleground for access. Whether it's PBMs or HTA bodies, the power dynamics are shifting.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.